Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'

Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.